ADHD Medication Comparison: Stimulants vs. Non-Stimulants

Stimulants Work Faster Than Almost Any Drug in Psychiatry

Amphetamine and methylphenidate produce clinically measurable ADHD symptom reduction within 30–60 minutes of the first dose. No washout period, no weeks-long titration before therapeutic benefit. This rapid onset distinguishes ADHD pharmacotherapy from virtually every other psychiatric medication class and makes the number-needed-to-treat (NNT) statistics among the most favorable in all of medicine. A 2018 Lancet meta-analysis (Cortese et al.) of 133 randomized trials involving more than 10,000 children and adults found amphetamines and methylphenidate to be the most efficacious short-term medications for ADHD in children, with NNTs in the range of 2–3 for core symptom reduction — meaning one in two or three treated patients achieves a clinically significant response that a placebo patient would not.

Mechanism: Two Different Targets on the Same System

Both amphetamines and methylphenidate work on catecholamine neurotransmission — dopamine and norepinephrine — but through distinct mechanisms that have clinical implications.

The additional efflux mechanism of amphetamines produces somewhat higher dopamine elevation per dose compared to methylphenidate — a difference that may explain why some patients respond to one class and not the other, and why amphetamines carry slightly higher abuse potential in head-to-head pharmacology studies. Clinical guidelines (including AHRQ and Canadian ADHD Resource Alliance guidelines) recommend trying one class before concluding non-response to stimulants.

Immediate-Release vs. Extended-Release Formulations

Formulation choice determines duration of coverage and practical dosing logistics as much as the molecule itself does.

Generic IR formulations are dramatically cheaper — monthly costs of $15–$40 vs. $200–$400+ for brand-name ER products. For patients with insurance gaps, twice-daily IR dosing is a financially accessible alternative with equivalent efficacy, at the cost of requiring a midday dose administered at school or work.

Non-Stimulant Options: NNT and Mechanisms

Non-stimulants are classified as Schedule V or unscheduled controlled substances (or not scheduled at all), making them accessible when stimulants are contraindicated, abused, or simply ineffective. Efficacy is lower on average than stimulants, but for specific patients they are the appropriate first choice.

• Atomoxetine (Strattera): A selective norepinephrine reuptake inhibitor (NRI) with no direct dopamine effect. NNT approximately 4–6, requiring 4–8 weeks for full effect. FDA-approved for ADHD in children, adolescents, and adults. Particularly useful in patients with comorbid anxiety (where stimulants may worsen symptoms) or a history of substance use disorder.
• Viloxazine (Qelbree): FDA-approved in 2021 for pediatric ADHD (6–17) and in 2023 for adults. A selective NE reuptake inhibitor with additional serotonin modulating activity. Clinical trials showed effect sizes (Cohen's d ~0.4–0.6) below stimulants but comparable to atomoxetine. Advantage: not a controlled substance.
• Guanfacine ER (Intuniv) and Clonidine ER (Kapvay): Alpha-2 adrenergic agonists that reduce norepinephrine signaling noise in the prefrontal cortex. Particularly effective for hyperactivity and impulsivity; less effect on inattention. Often used as adjuncts to stimulants or in children with tic disorders (where stimulants may exacerbate tics). Sedation and hypotension are primary adverse effects.
• Bupropion (off-label): A norepinephrine-dopamine reuptake inhibitor approved for depression and smoking cessation, used off-label for ADHD with modest evidence. NNT ~6–8. Useful in adults with comorbid depression.

Adverse Effects and Monitoring Framework

Stimulants share a predictable adverse effect profile related to sympathomimetic activity. The most clinically significant issues:

• Appetite suppression and growth: Long-term stimulant use in children may reduce height gain by approximately 1–2 cm over 3 years (MTA Cooperative Group follow-up data). Drug holidays (weekends, summers) can partially offset growth effects and are commonly recommended.
• Cardiovascular: Average increases of 1–4 mm Hg in blood pressure and 3–7 bpm in heart rate are typical. Absolute cardiac risk in children without pre-existing conditions remains very low; baseline ECG is recommended only in patients with cardiac history or symptoms, per AAP 2011 guidelines (revised 2023).
• Sleep: ER formulations taken in the morning can delay sleep onset by 30–60 minutes. Melatonin 0.5–3 mg is commonly used adjunctively; evidence base for pediatric melatonin in this indication is moderate.
• Psychiatric: Stimulants can precipitate or worsen anxiety, mania, and psychosis in susceptible individuals. Baseline psychiatric evaluation is essential; new-onset symptoms require reassessment of diagnosis and medication.

Adult ADHD: An Underdiagnosed Population

Adult ADHD prevalence is estimated at 2.5%–4% globally (Kessler et al., 2006 National Comorbidity Survey Replication). Until recently, adult ADHD was underrecognized: diagnosis rates in adults lagged children's rates by a factor of 4–5. The same medications approved for pediatric use are efficacious in adults, with adult trials showing comparable NNTs. Vyvanse received adult ADHD approval in 2008; viloxazine (Qelbree) adult approval came in 2023 — both filling significant gaps in the non-stimulant adult market.

This article is for informational and educational purposes only. Consult a qualified healthcare professional before making any medical decisions.